# A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct00229203/  
OnCo record `nct00229203` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Plitidepsin in Multiple myeloma, run by PharmaMar, completed.

## Summary

A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT00229203 by PharmaMar, with 51 participants recorded, started 2005-02 and reaching its primary completion in 2008-08. Interventions recorded: Plitidepsin. Conditions recorded: Multiple Myeloma.

Linked to the drug Plitidepsin because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00229203
- Phase: 2
- Setting: "Phase II Multicenter, Open-Label, Clinical and Pharmacokinetic Study of Aplidin® As A 3-Hour Infusion Every 2 Weeks Alone or in Combination With Dexamethasone, in Pre-Treated Patients With Relapsing or Refractory Multiple Myeloma."
- Sponsor: PharmaMar
- Enrolled: 51

## Sources

- ClinicalTrials.gov NCT00229203: https://clinicaltrials.gov/study/NCT00229203

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Plitidepsin](https://onco.cc/drugs/plitidepsin/)
- companies: [PharmaMar](https://onco.cc/companies/pharmamar/)

---
JSON: https://onco.cc/api/v1/entities/nct00229203.json